Austria’s Biocrates Life Sciences AG, a leading international biotechnology company, recently announced the completion of the first tranche of a new round of fund raising which has garnered €1.2 million. The financing round was led by Arax Capital Partners and joined by others, MIG being among them. The company expects another infusion of financing later this year in an amount at least equal to the current package. Biocrates plans to use the financing to further invest in its biomarker research projects.
Biocrates Life Sciences AG (www.biocrates.com)
Biocrates Life Sciences was established in 2002 to develop the Quartet Omics branch of systems biology. The company researches organic metabolism at the molecular level in order to create biomarkers for genetic research and applications. The technology developed from this research has wide-ranging implications for the medical and pharmaceutical industries. Biocrates is based in Innsbruck, Austria.